First human test of Triple-Threat cancer drug cocktail
NCT ID NCT01829568
Summary
This early-stage study aims to find the safest and most effective doses of two oral drugs, lenalidomide and ibrutinib, when given alongside the standard antibody drug rituximab. It involves 33 adults with previously untreated stage II-IV follicular lymphoma, a type of slow-growing blood cancer. The main goal is to understand the side effects and determine the best doses for future research, not to cure the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE III GRADE 1 FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.